Catherine Arnold

After a long product portfolio transition, we forecast that Bristol-Myers could return to a period of sustained high teens earnings read more

After a long product portfolio transition, we forecast that Bristol-Myers could return to a period of sustained high teens earnings per share growth in 2007-2010.

Schering-Plough shares are most likely to be impacted by first quarter 2006 results.

Schering-Plough shares are most likely to be impacted by first quarter 2006 results.

Lilly's current valuation still provides an attractive entry point. The stock trades at a modest 8% to 10% premium to read more

Lilly's current valuation still provides an attractive entry point. The stock trades at a modest 8% to 10% premium to its peers against 2006 and 2007 earnings and at a discount against our 2008 to 2010 forecast.

The U.S. case is more important because of the economic implications, ... It [the U.K. ruling] is a nice psychological read more

The U.S. case is more important because of the economic implications, ... It [the U.K. ruling] is a nice psychological boost but you can't extrapolate the U.S. ruling from this because of the different legal standards.

The U.S. case is more important because of the economic implications. [The U.K. ruling] is a nice psychological boost, but read more

The U.S. case is more important because of the economic implications. [The U.K. ruling] is a nice psychological boost, but you can't extrapolate the U.S. ruling from this because of the different legal standards.